William Blair Has Positive View of agilon health Q1 Earnings

agilon health, inc. (NYSE:AGL - Free Report) - Investment analysts at William Blair increased their Q1 2026 earnings per share (EPS) estimates for agilon health in a report released on Tuesday, May 6th. William Blair analyst R. Daniels now anticipates that the company will earn $0.09 per share for the quarter, up from their previous forecast of $0.05. The consensus estimate for agilon health's current full-year earnings is ($0.59) per share.

agilon health (NYSE:AGL - Get Free Report) last released its quarterly earnings results on Tuesday, May 6th. The company reported $0.03 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.04. agilon health had a negative return on equity of 47.84% and a negative net margin of 6.88%. The firm had revenue of $1.53 billion during the quarter, compared to the consensus estimate of $1.50 billion. During the same quarter in the prior year, the firm posted ($0.02) EPS. The business's revenue was down 4.5% on a year-over-year basis.

Other analysts also recently issued reports about the company. Sanford C. Bernstein upgraded agilon health from a "market perform" rating to an "outperform" rating and boosted their price target for the company from $3.30 to $8.50 in a research note on Tuesday, April 8th. Needham & Company LLC reissued a "hold" rating on shares of agilon health in a research report on Friday, March 21st. Citigroup raised shares of agilon health from a "neutral" rating to a "buy" rating and raised their price target for the stock from $3.25 to $5.00 in a research report on Friday, April 25th. JMP Securities reissued a "market perform" rating on shares of agilon health in a report on Monday, April 28th. Finally, Stifel Nicolaus raised their target price on shares of agilon health from $2.00 to $3.00 and gave the stock a "hold" rating in a report on Wednesday, February 26th. Two equities research analysts have rated the stock with a sell rating, twelve have issued a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $4.81.

agilon health Stock Performance

Shares of NYSE AGL opened at $3.40 on Thursday. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $1.40 billion, a P/E ratio of -3.61 and a beta of 0.38. agilon health has a 12 month low of $1.50 and a 12 month high of $7.73. The stock has a 50 day moving average of $4.27 and a 200-day moving average of $3.18.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. Oak Thistle LLC acquired a new stake in shares of agilon health in the 4th quarter valued at approximately $25,000. Ieq Capital LLC bought a new position in shares of agilon health in the 4th quarter valued at $26,000. Signaturefd LLC boosted its holdings in shares of agilon health by 143.0% during the 4th quarter. Signaturefd LLC now owns 14,388 shares of the company's stock valued at $27,000 after acquiring an additional 8,467 shares in the last quarter. Humankind Investments LLC bought a new stake in agilon health during the 4th quarter worth $30,000. Finally, Raymond James Financial Inc. bought a new position in agilon health in the fourth quarter valued at about $33,000.

agilon health Company Profile

agilon health, inc. provides healthcare services for seniors through primary care physicians in the communities of the United States. It offers a platform that manages the total healthcare needs of the patients by subscription-like per-member per-month. The company was formerly known as Agilon Health Topco, Inc and changed its name to agilon health, inc.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.